NASDAQ:PHAT Phathom Pharmaceuticals Q3 2026 Earnings Report $6.92 -0.16 (-2.26%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$7.02 +0.10 (+1.45%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Phathom Pharmaceuticals EPS ResultsActual EPSN/AConsensus EPS $0.07Beat/MissN/AOne Year Ago EPSN/APhathom Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$85.38 millionBeat/MissN/AYoY Revenue GrowthN/APhathom Pharmaceuticals Announcement DetailsQuarterQ3 2026Date10/29/2026TimeBefore Market OpensConference Call DateThursday, October 29, 2026Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Phathom Pharmaceuticals Earnings HeadlinesReviewing Traws Pharma (NASDAQ:TRAW) & Phathom Pharmaceuticals (NASDAQ:PHAT)October 1 at 4:29 AM | americanbankingnews.comPhathom Pharmaceuticals Starts Registrational Phase 3 Voquezna StudySeptember 30 at 8:36 AM | finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 3 at 1:00 AM | Stansberry Research (Ad)Phathom Pharmaceuticals, Inc. Initiates Registrational Phase 3 Study Of VOQUEZNA For As-Needed Treatment Of Non-Erosive GERDSeptember 29, 2026 | marketscreener.comMPhathom Pharmaceuticals avvia la fase 3 per VOQUEZNA nella NERDSeptember 29, 2026 | it.investing.comPhathom Pharmaceuticals Initiates Phase 3 Study of VOQUEZNA for As-Needed Treatment of Non-Erosive GERDSeptember 29, 2026 | quiverquant.comQSee More Phathom Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Phathom Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Phathom Pharmaceuticals and other key companies, straight to your email. Email Address About Phathom PharmaceuticalsPhathom Pharmaceuticals (NASDAQ:PHAT) is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s portfolio is centered on vonoprazan, a potassium-competitive acid blocker designed to suppress gastric acid production and provide an alternative to traditional proton pump inhibitors. Phathom markets vonoprazan in the United States under the brand name Voquezna. The product is approved for the healing and maintenance of healing of erosive esophagitis, relief of associated heartburn, and treatment of heartburn related to non-erosive gastroesophageal reflux disease. Voquezna is also approved, in combination with antibiotics, for the eradication of Helicobacter pylori, a bacterium associated with peptic ulcers and other gastrointestinal conditions. Phathom was established in 2018 and obtained U.S. rights to develop and commercialize vonoprazan through an agreement with Takeda Pharmaceutical Company. The company is headquartered in Buffalo Grove, Illinois, and is led by Chief Executive Officer Terrie Curran. Its commercial activities are primarily focused on the U.S. gastrointestinal market.View Phathom Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
